Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Nancy Rothwell | M | 68 |
The University of Manchester
| - |
| Robert Eric Hough | M | 79 |
The University of Manchester
| - |
| Sandip Mitra | M | - |
Renephra Ltd.
 Renephra Ltd. Miscellaneous Commercial ServicesCommercial Services Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom. | 15 anni |
| Rein Ulijn | M | - |
Renephra Ltd.
Renephra Ltd. Miscellaneous Commercial ServicesCommercial Services Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom. | - |
| Idalia Dawidowska | M | - |
Renephra Ltd.
Renephra Ltd. Miscellaneous Commercial ServicesCommercial Services Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom. | - |
| Kevin O'Brien | M | - |
The University of Manchester
| - |
| Mark D. Rahn | M | - |
Renephra Ltd.
Renephra Ltd. Miscellaneous Commercial ServicesCommercial Services Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom. | - |
| Charles McCollum | M | - |
The University of Manchester
| - |
| Geoffrey James Martin Parker | M | - |
The University of Manchester
| - |
| John Stageman | M | - |
The University of Manchester
| - |
| Norman Brian M. Askew | M | 82 |
The University of Manchester
| - |
| Dame Angela Strank | M | 71 |
The University of Manchester
| - |
| Anil Kumar Ruia | M | 68 |
The University of Manchester
| - |
| Diane Coyle | M | - |
The University of Manchester
| 10 anni |
| Philip Bruce Morgan | M | 55 |
The University of Manchester
| - |
| Ian Kimber | M | 74 |
The University of Manchester
| - |
| Jacky Smith | F | - |
The University of Manchester
| - |
| Bridget Lea | F | - |
The University of Manchester
| 6 anni |
| Cristiano Antonelli | M | 73 |
The University of Manchester
| - |
| Sandra Downes | M | - |
The University of Manchester
| - |
| Aimin Song | M | - |
The University of Manchester
| - |
| Alistair Taylor | M | - |
Renephra Ltd.
Renephra Ltd. Miscellaneous Commercial ServicesCommercial Services Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom. | - |
| Caroline Johnstone | F | 64 |
The University of Manchester
| - |
| Sheila Yeomans | F | - |
The University of Manchester
| 20 anni |
| Neville B. Richardson | M | 67 |
The University of Manchester
| - |
| Savvas Neophytou | M | 52 |
Renephra Ltd.
Renephra Ltd. Miscellaneous Commercial ServicesCommercial Services Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom. | - |
| Ian Horrocks | M | - |
The University of Manchester
| - |
| Ted Roberts | M | - |
The University of Manchester
| - |
| Roger Bruce Pettman | M | 68 |
The University of Manchester
| - |
| Edward Astle | M | 70 |
The University of Manchester
| - |
| Amin Rostami-Hodjegan | M | - |
The University of Manchester
| 23 anni |
| Stephen Shuttleworth | M | - |
The University of Manchester
| 10 anni |
| Stephen Toon | M | 68 |
The University of Manchester
| - |
| Ivan T. Robertson | M | - |
The University of Manchester
| - |
| Karl Wills | M | - |
The University of Manchester
| - |
| Paul O'Brien | M | - |
The University of Manchester
| - |
| Duncan Keeble | M | - |
Renephra Ltd.
Renephra Ltd. Miscellaneous Commercial ServicesCommercial Services Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom. | - |
| Xiao Chun Guo | M | 42 |
The University of Manchester
| - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Regno Unito | 38 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Paul Brenchley
- Contatti personali
